Lincoln Health Network’s second annual FWD Pharma Conference is set to draw an engaging lineup of marketing and brand practitioners from leading organizations and shine the spotlight on biotech and life-science strategies in a complex digital world. Slated to be held Aug. 31-Sept. 1, 2020, the event promises to amplify attendees’ digital transformation of commercial operations and market access through omnichannel engagements, campaign analytics and marketing automation. FWD Pharma 2020 will feature keynotes, interactive panels, case studies, hands-on workshops, and peer-to-peer learning opportunities. A diverse group of marketing and brand practitioners from leading life-sciences organizations will share successful strategies to instigate critical organizational change and insight on digital trends most prominent in today’s shifting landscape.
To view the full press release, visit http://ibn.fm/0NJo5
About Lincoln Health Network
Lincoln Health Network is the pharmaceutical, medical devices and life sciences go-to source for thought leadership and industry news. Research is driven through industry case studies – providing actionable data, benchmarking and insights into leading programs. Along with leading regulatory and compliance information, Lincoln Health Network’s events provide a dynamic platform for professionals to gain new education, expand networks and drive business results. Each conference, summit and workshop connects decision makers with peer networking, technology solutions and cutting-edge, peer-driven content. To learn more about Lincoln Health Network, visit: www.LincolnHealthNetwork.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights,…
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE…
HealthLynked (OTCQB: HLYK) has completed a reverse stock split as part of its strategy to…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of…
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data…
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an…